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Abstract
Background. This study aimed to assess the impact of wait times on patient survival following liver transplantation
for hepatocellular carcinoma (HCC) in a single donor service area. Patients and methods. Patients listed in the New
England Organ Bank (NEOB) from 1996 to 2005 for liver transplantation with a diagnosis of HCC were identified from
the United Network for Organ Sharing database. The following data were extracted: date of listing, date removed from
the wait list, indication for wait list removal, patient death and date of last known follow-up. Kaplan-Meier survival
estimates were calculated from the time of listing for transplant (intention to treat liver transplant survival, ITT OLT) and
compared to those calculated from the date of transplant (liver transplant, OLT). Results. There were 63 new registrations
to the transplant list during the study period. Sixty-one patients were removed from the waiting list: transplanted
41 (65%), death seven (11%), candidate condition deteriorated/too sick to transplant eight (13%), medically unsuitable one
(2%), other one (2%), transferred to another center two (3%), and transplanted at another center one (2%). Three-
year survival following liver transplantation for primary liver cancer was 85%. When the results were analyzed using an
intention to treat analysis there was a 1020% decrease in survival rate at every time point due to wait list drop-out.
Conclusion. Wait list drop-out adversely affects liver transplant survival in transplant centers served by the NEOB. These
data should be considered when recommending transplant versus resection as first line therapy for stage I or II HCC in our
region.
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Introduction
The optimal therapy for patients with hepatocellular
carcinoma (HCC), American Liver Tumor Study
Group Stage I or II remains controversial. While the
five-year survival rates appear equivalent in selected
patients undergoing either surgical resection or trans-
plantation, liver transplantation appears to offer the
best disease free survival [1]. Time to transplantation
is influenced by organ availability, which varies by
region; therefore, the decision for transplant versus
surgical resection as first line therapy should be in part
based on local/regional intention to treat survival rates
for both therapies. This study aimed to assess the
impact of wait times on patient survival following liver
transplantation for HCC in a donor specific area
(DSA).
Methods
Patients listed in the New England Organ Bank
(NEOB) and in the USA from 1996 to 2005 for liver
transplantation with a diagnosis of hepatoma/HCC,
hepatoma and cirrhosis, and fibrolamellar HCC
(primary liver cancer) were identified from the United
Network for Organ Sharing (UNOS) database. The
following data were extracted: date of listing for liver
transplant, date removed from the wait list, indication
for removal from the wait list, patient death and date
of last known follow-up.
Wait list drop-out was defined as removal from the
liver transplant wait list for any of the following
indications: medically unsuitable, candidate condi-
tion deteriorated/too sick to transplant, died and
other.
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The Kaplan-Meier survival estimates for all-cause
mortality was calculated For NEOB patients from the
time of listing for transplant (intention to treat liver
transplant survival, ITT OLT) and compared to that
calculated from the date of transplant (liver transplant,
OLT). Observations were right-censored at 20 April,
2007, based on the assumption that all deaths occurring
uptothisdatewouldhavebeen includedinthedatabase.
The log-rank statistic was used to cautiously assess the
leftward shift associated with an ITT OLT protocol.
Results
Registrations for liver transplantation for primary liver
cancer in Region I and in the USA are shown in Table
I. The data is shown for the 10-year study period.
Data for years 20042005 are reported separately to
reflect the most up-to-date Model for End-stage Liver
Disease (MELD) allocation variance for HCC. The
transplant rate for listed patients ranges from 64 to
72% with an upward trend in Region I following the
implementation of MELD.
Average wait time for transplanted patients was 143
days (range 2501 days).
Wait list drop-out was defined as removal from the
wait list for any of the following indications: death,
medically unsuitable, candidate condition deterio-
rated/too sick to transplant and other. Wait list drop-
out trended down following the implementation of
MELD in both NEOB and in the USA (2721%, p
0.48 and 2313%, p0.00001, respectively). Indica-
tions for wait list removal are shown in Table II.
Kaplan-Meier survival curves were calculated using
the methodology described previously. Survival was
calculated from the OLT survival and from the date of
listing for transplant (ITT OLT) (Figure 1). The
intention to treat survival is 1020% lower at every
time point when compared to OLT survival. This
difference is a result of wait list drop-out.
Discussion
Liver transplantation and surgical resection currently
represent the only curative therapies for HCC. While
ablation using radiofrequency, cryotherapy or micro-
wave technology may lead to complete necrosis in
up to 65% of small tumors (B3 cm), the results are
poorer for larger lesions (3 cm) and recurrence rates
remain high [10,11]. Transarterial chemoemboliza-
tion is an effective treatment for local control in
selected patients, but should not be considered a
stand alone therapy with curative intent.
Optimal therapy for patients with HCC, American
Liver Tumor Study Group Stage I or II remains
controversial. While five-year patient survival appears
equivalent in selected patients undergoing either
surgical resection or transplantation, liver transplan-
tation appears to offer the best disease free five-year
survival for those patients who actually receive a
transplant [1] (Table III).
Llovet et al. reported an 87 and 74% three- and five-
year survival, respectively with surgical resection for
HCC in selected patients without portal hypertension.
In their experience, when mean wait times for liver
Table I. Number of patients registered with UNOS in the New England Organ Bank (MAOB) and the USA with a diagnosis of primary
liver cancer.
Existing registrations New registrations At risk population* Transplanted (%) Dropout (%)
MAOB
20042005 11 32 43 31 (72%) 9 (21%)
19962005 1 63 64 42 (66%) 17 (27%)
USA
20042005 159 680 830 530 (64%) 108 (13%)
19962005 32 1812 1818 1200 (65%) 410 (23%)
*At risk population[(existing registrations at start of time periodnew registrations during time period)(number of patients removed
from wait list for the indication: candidate improved/transplant not warranted)].
Table II. Indications for removal from the liver transplant wait list for patients with a listing diagnosis of primary liver cancer.
Deceased donor liver
transplant Death Medically unsuitable
Candidate condition
deteriorated, too sick
to transplant Other
MAOB*
20042005 31 3 1 5 0
19962005 42 7 1 8 1
USA
2004 530 37 8 40 23
19962005 1200 182 17 145 66
*MAOB, New England Organ Bank.
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transplantation increased from 62 to 242 days, wait list
drop-out increased from 0 to 23% and ITT survival
for transplant decreased to 54% in two years [6].
Maraui et al. reported the New Zealand experience
for patients listed for liver transplantation with a
diagnosis of HCC within the Milan criteria. With a
median wait time of 63 days (range 0832 days) they
report a drop-out rate of 17% (10/59) and an ITT
five-year survival of 56% [3].
Yao et al. reported the cumulative probability of
wait list drop-out to be 7.3%, 25.3% and 43.6% at
six, 12 and 24 months, respectively in their experience
with mean wait times for blood group O and A
patients, listed as status 2B, exceeding 600 days. They
reported 11 drop outs in 46 patients listed for liver
transplantation with a diagnosis of HCC, with a two-
year intention to treat survival of 73% [5].
Cillo et al. reported an impressive 85% ITT
three-year survival in patients transplanted for HCC
exceeding the Milan criteria with a 69% ITT three-
year survival for patients within the Milan Criteria
with a median wait time of 11.8 months. The
difference in their results may be attributable to
bridging therapy for patients awaiting transplantation.
In their experience, 83/100 patients received some
form of treatment while awaiting transplantation
including surgical resection, radiofrequency ablation,
transarterial chemoembolization, alcohol injection or
some combination of these modalities [12].
Despite the excellent results reported by Cillo et al.
the impact of neoadjuvant treatment in patients
awaiting liver transplantation remains unclear with
conflicting reports in the literature and a lack of large
randomized, prospective studies [12,13].
In the present study, patients undergoing liver
transplantation for HCC in the NEOB DSA had an
85% three-year survival. When the survival data was
adjusted for wait list drop-out, a 1020% reduction in
Figure 1. Kaplan-Meier Survival estimates following liver transplantation for hepatocellular carcinoma. OLT, liver transplant survival; ITT
OLT, intention to treat liver transplant survival.
Table III. Survival following liver transplantation for primary liver cancer.
N One-year survival Three-year survival Five-year survival
Cillo [2]* 40 89% 71% 63%
Margarit [1] 36 78% 65%
Marui [3]* 59 56%
Broelsch [4] 46 61%
Yao [5] 46 91% 73%
Llovet [6]* 87 84% 69% 69%
Mazzaferro [7] 48 75%’
UNOS/OPTN 1201 86.3%t 70%£ 57.3%¥
*Intention to treat survival data.
’Four-year survival.
tBased on 20022004 transplants.
£Based on 19992002 transplants.
¥Based on 19972000 transplants.
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patient survival was noted at every time point out to
three years. This trend continues out to at least five
years; however, the present study was inadequately
powered to report the data beyond three years.
Survival following surgical resection for HCC in
selected candidates may be as high as 5775% at five
years (Table IV). These survival rates compare very
favorably to intention to treat survival rates for liver
transplantation in the NEOB DSA; making a case for
surgical resection as first line therapy.
There is no single, correct answer to the debate:
transplant versus resection for stage I and II HCC.
Liver transplantation offers the best disease-free survi-
val for patients who actually get transplanted; however,
transplant patients are subjected to wait list drop-out.
Surgical resection may offer a much shorter time to
definitive treatment, but has a higher rate of recurrence.
Wait times for liver transplantation vary by region
and DSA. In addition, ITT survival data for trans-
plantation and resection vary by center. The ideal
treatment for patients with stage I and II HCC should
be based on local experience, regional wait times and
individual program’s intention to treat survival for
both treatment modalities.
Limitations of our study include the following. First,
we are comparing liver transplant data from the NEOB
DSA to surgical resection data from the published
literature. Second, because wait times and outcomes
vary by region and center, we suggest caution in
applying the NEOB data to centers outside of our
DSA. Finally, our data are only relevant for selected
patients who are deemed potential candidates for both
surgical resection and liver transplantation based on
tumor size, location and degree of liver dysfunction.
In conclusion, there is no universally appropriate
answer to the debate of transplantation versus resec-
tion for treatment of stage I and II HCC. The
decision needs to be made based on local ITT survival
for both therapies, which will vary based on local wait
times for transplantation and experience.
Long wait times for liver transplantation result in
wait list drop-out which adversely affects ITT survival
in transplant centers served by the NEOB. These
data should be deliberately and actively used in the
patient counseling and decision-making process when
recommending transplant versus resection as first line
therapy for stage I or II HCC in our region.
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Table IV. Patient survival following surgical resection for primary liver cancer.
N One-year survival Three-year survival Five-year survival
Cillo [2]* 131 75% 52% 31% (58%)§
Tanaka [8] 86 89.6%
Margarit [1] 37 92% 70%
Broelsch [4] 139 65%
Fong [9] 154 81% 54% 37% (57%)§
Llovet [6]* 77 85% 62% 51% (75%)§
*Intention to treat survival data.
§Five-year survival in ‘‘best candidates’’ for surgical resection shown in parenthesis.
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